Bai Li Tian Heng: Iza-Bren's application for listing indications for triple-negative breast cancer has been accepted by the National Medical Products Administration's Drug Evaluation Center.

Bailey Tianheng WeChat public account announced on June 15th that the company's self-developed dual-target ADC drug Iza-Bren has officially received acceptance for market authorization application for the indication of triple-negative breast cancer from the National Medical Products Administration Drug Evaluation Center. This product is used for the treatment of locally advanced unresectable or metastatic triple-negative breast cancer patients who have previously failed treatment with taxanes. This is the third market authorization application accepted by the Evaluation Center, following nasopharyngeal cancer and esophageal squamous cell carcinoma.